Where the guideline stands	Insufficient evidence to recommend either way
Availability	Prescription
How long before you judge it	Variable
Pregnancy	Avoid; discuss with your clinician.
Sources behind this page	7, every one linked at the bottom

Bactrim for Acne at a glance. Recommendation strength and evidence certainty are separate axes under GRADE.

What it is

Trimethoprim/sulfamethoxazole (co-trimoxazole in the UK, Bactrim or Septra in the US) is a fixed combination of two antibiotics that block consecutive steps in the bacterial folate pathway. Starving the organism of folate stops it dividing. In acne the target is Cutibacterium acnes in the follicle, and the visible effect comes both from reducing that organism and from the drop in follicular inflammation that follows. Its approved indications are urinary tract infections, acute otitis media in children, acute exacerbations of chronic bronchitis, shigellosis, traveller’s diarrhoea and Pneumocystis jirovecii pneumonia. Acne is nowhere on that list, so an acne prescription is off-label, ordinary enough in dermatology, but worth knowing.

What the evidence actually shows

The 2024 AAD guideline grades three systemic antibiotics for acne (doxycycline, minocycline and sarecycline) and adds a conditional preference for doxycycline over azithromycin. Trimethoprim/sulfamethoxazole is not among the graded drugs. Add {“label”:”Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris (systemic antibiotics insufficient-evidence statement), J Am Acad Dermatol 2024;90(5):1006.e1-1006.e30″,”url”:”https://pubmed.ncbi.nlm.nih.gov/38300170/”} to the sources array. That is an explicit finding that the work group looked and could not make a recommendation either way, not a recommendation against it, and not silence. The underlying literature explains the silence. A 2007 review in Cutis (Bhambri, Del Rosso and Desai) gathers what exists. Hersle’s 1972 double-blind crossover study in Dermatologica randomised 43 patients to trimethoprim/sulfamethoxazole or placebo for five weeks and found a statistically significant improvement on the drug and none on placebo; two patients who had not responded to tetracycline improved markedly. A 1971 comparison of 42 patients against oxytetracycline over three months found the two roughly equivalent. A 1980 double-blind study of 30 patients, again against oxytetracycline, reached the same conclusion. An open study by Bottomley and Cunliffe in 1993 treated 56 patients whose acne had resisted previous antibiotics with trimethoprim plus topical clindamycin and reported marked improvement in both facial and truncal severity. That is close to the whole case: four small studies, the newest over thirty years old, none powered or designed to the standard a modern GRADE panel applies, and none compared against the drugs now used first. So the evidence is not absent; it is thin and old, which is a different problem and produces the same result. What keeps the drug in circulation is clinical experience with one specific situation: inflammatory or nodular acne that has failed tetracyclines, in someone not yet on, or not suited to, isotretinoin.

How it is actually used

This is a prescriber’s decision from a short list, not something to request. It tends to come up when tetracyclines have been tried and failed, or cannot be used at all, and usually while a longer-term plan (isotretinoin, a combined oral contraceptive, spironolactone) is being weighed. The guideline’s two good practice statements on systemic antibiotics apply here as much as anywhere: keep the course as short as possible, and use benzoyl peroxide alongside it. The label asks for complete blood counts and clinical chemistry to be done frequently during treatment, along with urinalysis and renal function tests, so this is not a prescription to take and forget. Any new rash while on it is a stop-and-call-now event rather than a wait-and-see one.

Safety and who should avoid it

This is the reason the drug sits where it does. The label warns that fatalities have occurred with sulfonamides, including severe cutaneous adverse reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) as well as fulminant hepatic necrosis, agranulocytosis and aplastic anaemia. These are rare, but they are not theoretical, and against an indication that is not life-threatening they weigh heavily. It is contraindicated in known hypersensitivity to trimethoprim or sulfonamides, in megaloblastic anaemia from folate deficiency, in marked hepatic damage or severe renal insufficiency, and in infants under two months. Hyperkalaemia and photosensitivity also occur. On pregnancy the label says the patient should be advised of potential hazards to the fetus; for acne specifically, that conversation usually ends the idea.

Commonly repeated: Bactrim is the standard next step after doxycycline for stubborn acne. What the evidence actually shows: it is a common next step in practice, but not a standard one on paper. The 2024 AAD guideline names it only to say the evidence is insufficient to make a recommendation either way, it has no FDA acne indication, and its acne trial base is a few small studies, the most recent of them from 1993.

Sources

Keep reading

See where this sits against every other acne treatment on the acne treatment evidence map, or check how it combines with another ingredient in the ingredient combination checker. For the guideline’s own wording on this, see the 2024 AAD guideline, recommendation by recommendation.

Not medical advice

This page reports what the published evidence says about a treatment. It is not a treatment plan and it cannot account for your skin, your other medications or your medical history. Nothing here has been reviewed by a clinician; see our editorial policy for what that means. Talk to a clinician before starting or stopping any prescription treatment.

Research, not medical advice. Every clinical claim above links to the guideline, systematic review, trial or drug label it came from, so you can check it yourself rather than take my word for it. It was researched and drafted with AI assistance by a non-clinician, and no dermatologist has reviewed it: this site does the reading, it doesn’t practise medicine. It can’t account for your circumstances either, so talk to a dermatologist or doctor about your own skin, especially before starting or stopping a prescription treatment.

Bactrim for Acne: What the Evidence Says